nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Hypoalbuminaemia—Dapsone—leprosy	0.0929	0.0929	CcSEcCtD
Tobramycin—Creatinine low—Thalidomide—leprosy	0.0542	0.0542	CcSEcCtD
Tobramycin—Blood creatinine decreased—Thalidomide—leprosy	0.0495	0.0495	CcSEcCtD
Tobramycin—Application site pain—Dapsone—leprosy	0.0461	0.0461	CcSEcCtD
Tobramycin—Rales—Thalidomide—leprosy	0.0253	0.0253	CcSEcCtD
Tobramycin—Proteinuria—Dapsone—leprosy	0.0231	0.0231	CcSEcCtD
Tobramycin—Protein urine present—Dapsone—leprosy	0.0228	0.0228	CcSEcCtD
Tobramycin—Platelet count decreased—Thalidomide—leprosy	0.0175	0.0175	CcSEcCtD
Tobramycin—Serum creatinine increased—Thalidomide—leprosy	0.0169	0.0169	CcSEcCtD
Tobramycin—Hypomagnesaemia—Thalidomide—leprosy	0.0163	0.0163	CcSEcCtD
Tobramycin—Lung disorder—Thalidomide—leprosy	0.0147	0.0147	CcSEcCtD
Tobramycin—Muscular weakness—Dapsone—leprosy	0.013	0.013	CcSEcCtD
Tobramycin—Apnoea—Thalidomide—leprosy	0.0122	0.0122	CcSEcCtD
Tobramycin—Proteinuria—Thalidomide—leprosy	0.0118	0.0118	CcSEcCtD
Tobramycin—Protein urine present—Thalidomide—leprosy	0.0117	0.0117	CcSEcCtD
Tobramycin—Bone disorder—Thalidomide—leprosy	0.0115	0.0115	CcSEcCtD
Tobramycin—Hypocalcaemia—Thalidomide—leprosy	0.0113	0.0113	CcSEcCtD
Tobramycin—Oliguria—Thalidomide—leprosy	0.0113	0.0113	CcSEcCtD
Tobramycin—Drug interaction—Thalidomide—leprosy	0.0112	0.0112	CcSEcCtD
Tobramycin—Neuropathy peripheral—Dapsone—leprosy	0.0111	0.0111	CcSEcCtD
Tobramycin—Leukocytosis—Thalidomide—leprosy	0.011	0.011	CcSEcCtD
Tobramycin—Hearing impaired—Thalidomide—leprosy	0.0109	0.0109	CcSEcCtD
Tobramycin—Creatinine increased—Thalidomide—leprosy	0.0109	0.0109	CcSEcCtD
Tobramycin—Sinusitis—Dapsone—leprosy	0.0106	0.0106	CcSEcCtD
Tobramycin—Phosphatase alkaline increased—Thalidomide—leprosy	0.0104	0.0104	CcSEcCtD
Tobramycin—Pharyngitis—Dapsone—leprosy	0.0101	0.0101	CcSEcCtD
Tobramycin—Dry eye—Thalidomide—leprosy	0.00959	0.00959	CcSEcCtD
Tobramycin—Tinnitus—Dapsone—leprosy	0.0095	0.0095	CcSEcCtD
Tobramycin—Rash maculo-papular—Thalidomide—leprosy	0.00944	0.00944	CcSEcCtD
Tobramycin—Erythema—Dapsone—leprosy	0.00887	0.00887	CcSEcCtD
Tobramycin—Thrombophlebitis—Thalidomide—leprosy	0.00871	0.00871	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00866	0.00866	CcSEcCtD
Tobramycin—Deafness—Thalidomide—leprosy	0.00842	0.00842	CcSEcCtD
Tobramycin—Vision blurred—Dapsone—leprosy	0.00835	0.00835	CcSEcCtD
Tobramycin—Eye pain—Thalidomide—leprosy	0.00835	0.00835	CcSEcCtD
Tobramycin—Renal failure acute—Thalidomide—leprosy	0.00816	0.00816	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Thalidomide—leprosy	0.00799	0.00799	CcSEcCtD
Tobramycin—Vertigo—Dapsone—leprosy	0.00796	0.00796	CcSEcCtD
Tobramycin—Cough—Dapsone—leprosy	0.00774	0.00774	CcSEcCtD
Tobramycin—Lethargy—Thalidomide—leprosy	0.00769	0.00769	CcSEcCtD
Tobramycin—Blood creatinine increased—Thalidomide—leprosy	0.00706	0.00706	CcSEcCtD
Tobramycin—Dehydration—Thalidomide—leprosy	0.00701	0.00701	CcSEcCtD
Tobramycin—Dry skin—Thalidomide—leprosy	0.00691	0.00691	CcSEcCtD
Tobramycin—Hypokalaemia—Thalidomide—leprosy	0.00686	0.00686	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Thalidomide—leprosy	0.00679	0.00679	CcSEcCtD
Tobramycin—Muscular weakness—Thalidomide—leprosy	0.00665	0.00665	CcSEcCtD
Tobramycin—Eosinophilia—Thalidomide—leprosy	0.00645	0.00645	CcSEcCtD
Tobramycin—Bronchospasm—Thalidomide—leprosy	0.00641	0.00641	CcSEcCtD
Tobramycin—Bronchitis—Thalidomide—leprosy	0.00626	0.00626	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Thalidomide—leprosy	0.00605	0.00605	CcSEcCtD
Tobramycin—Gastrointestinal pain—Dapsone—leprosy	0.00592	0.00592	CcSEcCtD
Tobramycin—Weight decreased—Thalidomide—leprosy	0.00589	0.00589	CcSEcCtD
Tobramycin—Infestation NOS—Thalidomide—leprosy	0.00581	0.00581	CcSEcCtD
Tobramycin—Infestation—Thalidomide—leprosy	0.00581	0.00581	CcSEcCtD
Tobramycin—Abdominal pain—Dapsone—leprosy	0.00572	0.00572	CcSEcCtD
Tobramycin—Body temperature increased—Dapsone—leprosy	0.00572	0.00572	CcSEcCtD
Tobramycin—Renal failure—Thalidomide—leprosy	0.00571	0.00571	CcSEcCtD
Tobramycin—Neuropathy peripheral—Thalidomide—leprosy	0.00569	0.00569	CcSEcCtD
Tobramycin—Stomatitis—Thalidomide—leprosy	0.00566	0.00566	CcSEcCtD
Tobramycin—Epistaxis—Thalidomide—leprosy	0.00548	0.00548	CcSEcCtD
Tobramycin—Sinusitis—Thalidomide—leprosy	0.00545	0.00545	CcSEcCtD
Tobramycin—Agranulocytosis—Thalidomide—leprosy	0.00542	0.00542	CcSEcCtD
Tobramycin—Rhinitis—Thalidomide—leprosy	0.00523	0.00523	CcSEcCtD
Tobramycin—Pharyngitis—Thalidomide—leprosy	0.00517	0.00517	CcSEcCtD
Tobramycin—Urinary tract disorder—Thalidomide—leprosy	0.00515	0.00515	CcSEcCtD
Tobramycin—Urethral disorder—Thalidomide—leprosy	0.00511	0.00511	CcSEcCtD
Tobramycin—Visual impairment—Thalidomide—leprosy	0.00502	0.00502	CcSEcCtD
Tobramycin—Eye disorder—Thalidomide—leprosy	0.00487	0.00487	CcSEcCtD
Tobramycin—Tinnitus—Thalidomide—leprosy	0.00486	0.00486	CcSEcCtD
Tobramycin—Angiopathy—Thalidomide—leprosy	0.00473	0.00473	CcSEcCtD
Tobramycin—Immune system disorder—Thalidomide—leprosy	0.00471	0.00471	CcSEcCtD
Tobramycin—Mediastinal disorder—Thalidomide—leprosy	0.0047	0.0047	CcSEcCtD
Tobramycin—Vomiting—Dapsone—leprosy	0.0046	0.0046	CcSEcCtD
Tobramycin—Headache—Dapsone—leprosy	0.00453	0.00453	CcSEcCtD
Tobramycin—Dysgeusia—Thalidomide—leprosy	0.00444	0.00444	CcSEcCtD
Tobramycin—Back pain—Thalidomide—leprosy	0.00439	0.00439	CcSEcCtD
Tobramycin—Nausea—Dapsone—leprosy	0.0043	0.0043	CcSEcCtD
Tobramycin—Vision blurred—Thalidomide—leprosy	0.00428	0.00428	CcSEcCtD
Tobramycin—Ill-defined disorder—Thalidomide—leprosy	0.00421	0.00421	CcSEcCtD
Tobramycin—Anaemia—Thalidomide—leprosy	0.00419	0.00419	CcSEcCtD
Tobramycin—Angioedema—Thalidomide—leprosy	0.00415	0.00415	CcSEcCtD
Tobramycin—Malaise—Thalidomide—leprosy	0.00409	0.00409	CcSEcCtD
Tobramycin—Vertigo—Thalidomide—leprosy	0.00408	0.00408	CcSEcCtD
Tobramycin—Leukopenia—Thalidomide—leprosy	0.00406	0.00406	CcSEcCtD
Tobramycin—Cough—Thalidomide—leprosy	0.00396	0.00396	CcSEcCtD
Tobramycin—Chest pain—Thalidomide—leprosy	0.00386	0.00386	CcSEcCtD
Tobramycin—Myalgia—Thalidomide—leprosy	0.00386	0.00386	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00384	0.00384	CcSEcCtD
Tobramycin—Discomfort—Thalidomide—leprosy	0.00382	0.00382	CcSEcCtD
Tobramycin—Confusional state—Thalidomide—leprosy	0.00373	0.00373	CcSEcCtD
Tobramycin—Nervous system disorder—Thalidomide—leprosy	0.00363	0.00363	CcSEcCtD
Tobramycin—Thrombocytopenia—Thalidomide—leprosy	0.00363	0.00363	CcSEcCtD
Tobramycin—Skin disorder—Thalidomide—leprosy	0.0036	0.0036	CcSEcCtD
Tobramycin—Anorexia—Thalidomide—leprosy	0.00353	0.00353	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Thalidomide—leprosy	0.00337	0.00337	CcSEcCtD
Tobramycin—Paraesthesia—Thalidomide—leprosy	0.00333	0.00333	CcSEcCtD
Tobramycin—Dyspnoea—Thalidomide—leprosy	0.0033	0.0033	CcSEcCtD
Tobramycin—Decreased appetite—Thalidomide—leprosy	0.00322	0.00322	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Thalidomide—leprosy	0.0032	0.0032	CcSEcCtD
Tobramycin—Pain—Thalidomide—leprosy	0.00317	0.00317	CcSEcCtD
Tobramycin—Feeling abnormal—Thalidomide—leprosy	0.00305	0.00305	CcSEcCtD
Tobramycin—Gastrointestinal pain—Thalidomide—leprosy	0.00303	0.00303	CcSEcCtD
Tobramycin—Urticaria—Thalidomide—leprosy	0.00294	0.00294	CcSEcCtD
Tobramycin—Abdominal pain—Thalidomide—leprosy	0.00293	0.00293	CcSEcCtD
Tobramycin—Body temperature increased—Thalidomide—leprosy	0.00293	0.00293	CcSEcCtD
Tobramycin—Hypersensitivity—Thalidomide—leprosy	0.00273	0.00273	CcSEcCtD
Tobramycin—Asthenia—Thalidomide—leprosy	0.00266	0.00266	CcSEcCtD
Tobramycin—Pruritus—Thalidomide—leprosy	0.00262	0.00262	CcSEcCtD
Tobramycin—Diarrhoea—Thalidomide—leprosy	0.00253	0.00253	CcSEcCtD
Tobramycin—Dizziness—Thalidomide—leprosy	0.00245	0.00245	CcSEcCtD
Tobramycin—Vomiting—Thalidomide—leprosy	0.00235	0.00235	CcSEcCtD
Tobramycin—Rash—Thalidomide—leprosy	0.00234	0.00234	CcSEcCtD
Tobramycin—Dermatitis—Thalidomide—leprosy	0.00233	0.00233	CcSEcCtD
Tobramycin—Headache—Thalidomide—leprosy	0.00232	0.00232	CcSEcCtD
Tobramycin—Nausea—Thalidomide—leprosy	0.0022	0.0022	CcSEcCtD
